2026 Nobel Prize in Medicine Awarded for Breakthroughs in Optogenetics
The 2026 Nobel Prize in Medicine is awarded to Karl Deisseroth, Peter Hegemann, and Georg Nagel for pioneering discoveries in optogenetics, enabling precise control of neural activity using light.
The 2026 Nobel Prize in Medicine has been awarded to Karl Deisseroth from Stanford University in the USA, Peter Hegemann from Humboldt University in Berlin, and Georg Nagel from the University of Würzburg in Germany for their groundbreaking discoveries in optogenetics—controlling cell activity using light.
This discovery enables a novel approach to precise control over nerve cells to influence brain activity for research and therapeutic purposes. By genetically engineering specific cells to respond to light, researchers can deliver precise pulses to excite particular nerve cells in a way currently unmatched by any other method.
To engineer cells to respond to light, scientists utilize opsins, which are light-sensitive neural receptors already found in living organisms, such as the retina, converting light into electrical activity in nerve cells. Through genetic engineering, these are coded into cells that do not normally express them, allowing any chosen cell to react to light.
Hegemann and Nagel jointly discovered the light-responsive channels, a discovery considered the foundation of the field. Deisseroth was the first to use this technology to stimulate neurons. Both Deisseroth and Hegemann previously received the Harvey Prize awarded by the Technion.
Currently, the application of this technology is primarily research-oriented, having been used to map brain activity characterizing conditions such as anxiety, various types of memory, hunger, thirst, and motor patterns. Future applications may enable stimulation of specific cells to improve brain function, including in diseases such as epilepsy, Parkinson's, or depression.
